Eisai's Partnership Initiatives

Eisai aims to improve business efficiency and productivity and promptly maximize contribution to patients by leveraging global partnerships.

  • *
    Details of the agreements below are as of the end of March 2020.

Strategic Collaboration

*You can scroll to the left or right here

Party to contractDate of conclusionContract content
Biogen (U.S.A.)
March 4, 2014
1. Acquisition of option rights for co-development/co-promotion of the Eisai-developed anti-amyloid beta (Aβ) protofibril antibody BAN2401 and the BACE inhibitor E2609 (generic name: elenbecestat)*1, and co-development/co-promotion of a Biogen-developed anti-tau antibody
2. Co-development/co-promotion of the Biogen-developed anti-Aβ antibody BIIB037 (generic name: aducanumab)
U.S. Merck
March 7, 2018
Co-development/co-promotion of Eisai’s anticancer agent Lenvima as monotherapy and in combination with U.S. Merck’s anti-PD-1 antibody Keytruda for a number of cancer types
Nichi-Iko Pharmaceutical Co., Ltd.*2
March 28, 2018
1. Collaboration in building the Company’s Total Inclusive Ecosystem
2. Partnership in the active pharmaceutical ingredient business
*1 In September 2019, Biogen and Eisai discontinued Phase III testing to verify the efficacy and safety of E2609 (generic name: elenbecestat).
*2 In April 2019, the Company completed the gradual transfer of shares of Elmed Eisai, Co., Ltd. stock.

Licensing

*You can scroll to the left or right here

Party to contractDate of conclusionContract content
Fujifilm Corporation
Toyama Chemical Co., Ltd.
September 30, 1998
Joint development of and marketing alliance for the rheumatoid arthritis agent Careram (generic name: iguratimod)
AbbVie Deutschland GmbH & Co. KG (Germany)
June 16, 1999 Development and sale of the fully human anti-TNF-α monoclonal antibody Humira (generic name: adalimumab) in Japan, Taiwan*3, and South Korea
Novartis AG (Switzerland)
February 6, 2004 License for worldwide development, manufacturing, and sale of the antiepileptic agent Inovelon (generic name: rufinamide)
Sunovion Pharmaceuticals Inc. (U.S.A.)
July 26, 2007 Exclusive license for the development and marketing of the insomnia treatment Lunesta (generic name: eszopiclone) in Japan
BioArctic (Sweden)
December 3, 2007 Exclusive license for worldwide research and development, manufacturing, and sale of the anti-Aβ protofibrils antibody BAN2401 for the treatment of Alzheimer’s disease
Pfizer Inc. (U.S.A.)
September 24, 2009 Co-promotion agreement in Japan for the pain treatment agent Lyrica (generic name: pregabalin)
Prism BioLab Co., Ltd.
April 1, 2011
Exclusive license for worldwide development, manufacturing, and sale of the anticancer agent E7386
University of London (U.K.)
October 16, 2015 Collaborative research and co-development of the anti-tau antibody E2814
Meiji Seika Pharma Co., Ltd.
March 31, 2017 Licenses related to exclusive sales rights in Japan and exclusive development and sales rights in 7 Asian countries for the anti-Parkinson’s disease agent Equfina (generic name: safinamide)
Harvard University (U.S.A.)
June 15, 2018
Exclusive license for worldwide development, manufacturing, and sale of anticancer agent E7130
Gilead Sciences, Inc.
December 24, 2019
Marketing alliance contract for the selective Janus kinase 1 inhibitor filgotinib (generic name) in Japan
Minophagen Pharmaceutical Co., Ltd.
February 29, 2016
Exclusive development and sales rights of the liver disease/ allergic disease agents Stronger Neo-Minophagen C (glycyrrhizic acid, compound formulation) and Glycyron Tablets (glycyrrhizic acid, compound tablet) in Japan and other Euro-Asian countries where the products have not yet been sold, and exclusive first negotiation rights in China and other Euro-Asian countries where the products are already sold
*3 In August 2019, the contract for development and sale of Humira in Taiwan ended.

Joint Venture

*You can scroll to the left or right here

Party to contractDate of conclusionContract content
Ajinomoto Co., Inc. October 15, 2015 Integration agreement concerning the splitting off of a portion of Eisai’s business and its subsequent succession by Ajinomoto Pharmaceuticals Co., Ltd. via an absorption-type split, etc.

Other Contracts Important for Business

*You can scroll to the left or right here

Party to contractDate of conclusionContract content
World Health Organization (WHO) (Switzerland)
January 30, 2012 Provision of DEC (generic name: diethylcarbamazine) tablets to the WHO free of charge to support its program to eliminate lymphatic filariasis

Sustainability